Relationship Between High-mobility Group Box 1 Overexpression in Ovarian Cancer Tissue and Serum: a Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2015 Dec 15

PMID 26664135

Citations 9

Authors

Haipeng Wang

Zengjun Li

Yanlai Sun

Zhongfa Xu

Jianjun Han

Bao Song

Wentao Song

Chen Qin

Lei Yin

Affiliations

Soon will be listed here.

Abstract

Objective: To implement a meta-analysis to investigate the relationship between high-mobility group box 1 (HMGB1) overexpression in the tissue and serum of ovarian cancer patients, and to evaluate its prognostic significance.

Methods: Searches were made of China National Knowledge Infrastructure, EMBASE, WanFang, PubMed, MEDLINE, and Web of Science databases up to August 2015, with no language or style restrictions. Reference lists of related studies were also carefully reviewed to identify additional articles.

Results: The literature search identified a total of 12 relevant studies on HMGB1 expression for inclusion in the meta-analysis: seven in ovarian tumor tissue, four in ovarian tumor patient serum, and one in both tissue and serum. HMGB1 protein levels in ovarian cancer tissues were notably higher than those in normal ovarian tissues with no evidence of heterogeneity between studies (RD=0.64, 95% confidence interval (CI): 0.57-0.70, Z=18.70, P<0.00001, I (2)=15%), and also higher than those in benign tumor tissues with no evidence of heterogeneity between studies (RD=0.52, 95% CI: 0.43-0.61, Z=11.14, P<0.00001, I (2)=0). Serum HMGB1 levels were similarly significantly higher in ovarian cancer patients than those with benign tumors or normal ovaries. Pooled mean differences of HMGB1 in ovarian cancer patients compared with patients with benign tumors or normal ovaries were 99.32 with 95% CI: 67.82-130.81, Z=6.18, P<0.00001, and 95.34 with 95% CI: 62.11-128.57, Z=5.62, P<0.0001. The pooled relative risk of ovarian cancer with high vs low HMGB1 expression levels was 1.40 with 95% CI: 1.09-1.79, Z=2.66, P=0.008, heterogeneity I (2)=50%.

Conclusion: This meta-analysis suggested that HMGB1 levels in both tissue and serum of ovarian cancer patients were significantly higher than those of benign tumor and normal ovarian samples. High serum or tissue HMGB1 expression may therefore be an effective molecular marker for ovarian benign or malignant tumor diagnosis and patient prognosis.

Citing Articles

The SIRT1-HMGB1 axis: Therapeutic potential to ameliorate inflammatory responses and tumor occurrence.

Wei L, Zhang W, Li Y, Zhai J Front Cell Dev Biol. 2022; 10:986511.

PMID: 36081910 PMC: 9448523. DOI: 10.3389/fcell.2022.986511.

The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response.

Camara-Quilez M, Barreiro-Alonso A, Vizoso-Vazquez A, Rodriguez-Belmonte E, Quindos-Varela M, Lamas-Maceiras M Cancers (Basel). 2020; 12(9).

PMID: 32867128 PMC: 7564582. DOI: 10.3390/cancers12092435.

In search of the altering salivary proteome in metastatic breast and ovarian cancers.

Giri K, Mehta A, Ambatipudi K FASEB Bioadv. 2020; 1(3):191-207.

PMID: 32123828 PMC: 6996400. DOI: 10.1096/fba.2018-00029.

Inhibition of Triple-Negative Breast Cancer Cell Aggressiveness by Cathepsin D Blockage: Role of Annexin A1.

Pereira Zoia M, Azevedo F, Vecchi L, Soares Mota S, de Rezende Rodovalho V, Cordeiro A Int J Mol Sci. 2019; 20(6).

PMID: 30884823 PMC: 6471925. DOI: 10.3390/ijms20061337.

No association between HMGB1 polymorphisms and cancer risk: evidence from a meta-analysis.

Li X, Liang C, Yang Y, Liu L, Du Y, Liang H Biosci Rep. 2018; 38(5).

PMID: 30049847 PMC: 6123066. DOI: 10.1042/BSR20180658.

References

Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A . Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003; 22(20):5551-60. PMC: 213771. DOI: 10.1093/emboj/cdg516. View

Chung H, Lee S, Kim H, Hong D, Chung J, Stroncek D . Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med. 2009; 7:38. PMC: 2694170. DOI: 10.1186/1479-5876-7-38. View

Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G . Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol. 2009; 136(5):677-84. DOI: 10.1007/s00432-009-0706-1. View

Semino C, Angelini G, Poggi A, Rubartelli A . NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood. 2005; 106(2):609-16. DOI: 10.1182/blood-2004-10-3906. View

Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H . Serum high mobility group box protein 1 as a clinical marker for ovarian cancer. Neoplasma. 2014; 61(5):579-84. DOI: 10.4149/neo_2014_070. View

Taguchi A, Blood D, Del Toro G, Canet A, Lee D, Qu W . Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000; 405(6784):354-60. DOI: 10.1038/35012626. View

Akaike H, Kono K, Sugai H, Takahashi A, Mimura K, Kawaguchi Y . Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res. 2007; 27(1A):449-57. View

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

10.

Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A . Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004; 164(3):441-9. PMC: 2172232. DOI: 10.1083/jcb.200304135. View

11.

Park S, Lee S, Kim H, Lee W, Hong K, Kim C . HMGB1 induces angiogenesis in rheumatoid arthritis via HIF-1α activation. Eur J Immunol. 2014; 45(4):1216-27. DOI: 10.1002/eji.201444908. View

12.

Huttunen H, Fages C, Kuja-Panula J, Ridley A, Rauvala H . Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 2002; 62(16):4805-11. View

13.

Chen J, Liu X, Zhang J, Zhao Y . Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol. 2012; 227(11):3629-38. DOI: 10.1002/jcp.24069. View

14.

Ueda M, Takahashi Y, Shinden Y, Sakimura S, Hirata H, Uchi R . Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer. Anticancer Res. 2014; 34(10):5357-62. View

15.

Meng Q, Zhao J, Liu H, Zhou G, Zhang W, Xu X . HMGB1 promotes cellular proliferation and invasion, suppresses cellular apoptosis in osteosarcoma. Tumour Biol. 2014; 35(12):12265-74. DOI: 10.1007/s13277-014-2535-3. View

16.

Singh A, Feng Y, Mahato N, Li J, Wu C, Gong J . Role of high-mobility group box 1 in patients with acute obstructive suppurative cholangitis-induced sepsis. J Inflamm Res. 2015; 8:71-7. PMC: 4362899. DOI: 10.2147/JIR.S77539. View

17.

Qin W, Mi S, Li C, Wang G, Zhang J, Wang H . Low shear stress induced HMGB1 translocation and release via PECAM-1/PARP-1 pathway to induce inflammation response. PLoS One. 2015; 10(3):e0120586. PMC: 4368774. DOI: 10.1371/journal.pone.0120586. View

18.

Paek J, Lee M, Nam E, Kim S, Kim Y . Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. Arch Gynecol Obstet. 2015; 293(3):645-50. DOI: 10.1007/s00404-015-3864-1. View

19.

Agresti A, Scaffidi P, Riva A, Caiolfa V, Bianchi M . GR and HMGB1 interact only within chromatin and influence each other's residence time. Mol Cell. 2005; 18(1):109-21. DOI: 10.1016/j.molcel.2005.03.005. View

20.

Chung H, Lim J, Jang S, Lee K, Park K, Song S . Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci. 2012; 103(9):1714-21. PMC: 7659219. DOI: 10.1111/j.1349-7006.2012.02358.x. View